These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 29232304)

  • 1. Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.
    Bisschop C; Ter Elst A; Bosman LJ; Platteel I; Jalving M; van den Berg A; Diepstra A; van Hemel B; Diercks GFH; Hospers GAP; Schuuring E
    Melanoma Res; 2018 Apr; 28(2):96-104. PubMed ID: 29232304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma.
    Melchior L; Grauslund M; Bellosillo B; Montagut C; Torres E; Moragón E; Micalessi I; Frans J; Noten V; Bourgain C; Vriesema R; van der Geize R; Cokelaere K; Vercooren N; Crul K; Rüdiger T; Buchmüller D; Reijans M; Jans C
    Exp Mol Pathol; 2015 Dec; 99(3):485-91. PubMed ID: 26407762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay.
    Vallée A; Denis-Musquer M; Herbreteau G; Théoleyre S; Bossard C; Denis MG
    PLoS One; 2019; 14(8):e0221123. PubMed ID: 31415669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system.
    Janku F; Claes B; Huang HJ; Falchook GS; Devogelaere B; Kockx M; Bempt IV; Reijans M; Naing A; Fu S; Piha-Paul SA; Hong DS; Holley VR; Tsimberidou AM; Stepanek VM; Patel SP; Kopetz ES; Subbiah V; Wheler JJ; Zinner RG; Karp DD; Luthra R; Roy-Chowdhuri S; Sablon E; Meric-Bernstam F; Maertens G; Kurzrock R
    Oncotarget; 2015 Sep; 6(29):26886-94. PubMed ID: 26330075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
    Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
    Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid clinical mutational testing of
    Van Haele M; Vander Borght S; Ceulemans A; Wieërs M; Metsu S; Sagaert X; Weynand B
    J Clin Pathol; 2020 Jan; 73(1):35-41. PubMed ID: 31296605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
    Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
    Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.
    O'Brien O; Lyons T; Murphy S; Feeley L; Power D; Heffron CCBB
    J Clin Pathol; 2017 Nov; 70(11):935-940. PubMed ID: 28424234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The usefulness of a novel fully automated PCR-based Idylla test for detection of the BRAF V600E mutation in thyroid tissue: comparison with PNA-clamping PCR, real-time PCR and pyrosequencing.
    Yeo MK; Jung MK; Lee SY; Lee YM; Hur GM; Kim JM
    J Clin Pathol; 2017 Mar; 70(3):260-265. PubMed ID: 27543599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.
    Halait H; Demartin K; Shah S; Soviero S; Langland R; Cheng S; Hillman G; Wu L; Lawrence HJ
    Diagn Mol Pathol; 2012 Mar; 21(1):1-8. PubMed ID: 22306669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter Evaluation of a Novel Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues.
    Schiefer AI; Parlow L; Gabler L; Mesteri I; Koperek O; von Deimling A; Streubel B; Preusser M; Lehmann A; Kellner U; Pauwels P; Lambin S; Dietel M; Hummel M; Klauschen F; Birner P; Möbs M
    J Mol Diagn; 2016 May; 18(3):370-377. PubMed ID: 26921540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of BRAF V600E Mutation in Ganglioglioma and Pilocytic Astrocytoma by Immunohistochemistry and Real-Time PCR-Based Idylla Test.
    Durślewicz J; Klimaszewska-Wiśniewska A; Antosik P; Kasperska A; Grzanka D; Szylberg T; Szylberg Ł
    Dis Markers; 2020; 2020():8880548. PubMed ID: 32879641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.
    Colomba E; Hélias-Rodzewicz Z; Von Deimling A; Marin C; Terrones N; Pechaud D; Surel S; Côté JF; Peschaud F; Capper D; Blons H; Zimmermann U; Clerici T; Saiag P; Emile JF
    J Mol Diagn; 2013 Jan; 15(1):94-100. PubMed ID: 23159108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.
    Huang WK; Kuo TT; Wu CE; Cheng HY; Hsieh CH; Hsieh JJ; Shen YC; Hou MM; Hsu T; Chang JW
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):403-408. PubMed ID: 27488807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays.
    Fisher KE; Cohen C; Siddiqui MT; Palma JF; Lipford EH; Longshore JW
    Hum Pathol; 2014 Nov; 45(11):2281-93. PubMed ID: 25228337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Utility and evaluation of immunohistochemical detection of BRAF V600E mutation in melanoma].
    Lyu JJ; Kong YY; Cai X; Shen XX; Lu YW; Ren M
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):548-552. PubMed ID: 28810295
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.
    Ihle MA; Fassunke J; König K; Grünewald I; Schlaak M; Kreuzberg N; Tietze L; Schildhaus HU; Büttner R; Merkelbach-Bruse S
    BMC Cancer; 2014 Jan; 14():13. PubMed ID: 24410877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma.
    Franczak C; Salleron J; Dubois C; Filhine-Trésarrieu P; Leroux A; Merlin JL; Harlé A
    Mol Diagn Ther; 2017 Apr; 21(2):209-216. PubMed ID: 28130756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue.
    Johnston L; Power M; Sloan P; Long A; Silmon A; Chaffey B; Lisgo AJ; Little L; Vercauteren E; Steiniche T; Meyer T; Simpson J
    J Clin Pathol; 2018 Apr; 71(4):336-343. PubMed ID: 28899979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
    Yaman B; Kandiloğlu G; Akalin T
    Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.